COVID-19大流行对肿瘤FDG PET/CT分期时疾病范围的影响:ONCOVIPET研究
该回顾性观察研究纳入2019年与2020年6月1日至10月31日接受FDG PET/CT分期的肿瘤患者,比较两次疫情前后疾病范围。2020年较2019年晚期疾病患者率比为1.56(P<0.001),淋巴结或远处转移患者及受累站数均显著增加。作者认为需针对性卫生干预以减轻疫情对患者结局的影响。
要点
- 2020年较2019年FDG PET/CT分期时晚期疾病患者率比为1.56(P<0.001)。
- 2020年淋巴结阳性或远处转移患者率比分别为1.84和2.09(P<0.001)。
- 淋巴瘤和肺癌的晚期疾病在2020年较2019年显著增加(P<0.001)。
核心结论
- 2020年FDG PET/CT分期时晚期疾病肿瘤患者较2019年增加,为1.5倍,淋巴结或远处转移患者显著增加。
- 作者认为需要针对性卫生干预以减轻疫情对患者结局的影响。
研究设计与样本
- 回顾性观察研究,纳入2019年6月1日至10月31日和2020年6月1日至10月31日接受FDG PET/CT分期的肿瘤患者。
- 共纳入611例患者,2019年240例,2020年371例。
- 收集原发肿瘤、淋巴结(N)状态及受累淋巴结站数、远处转移(M)存在及数量,每份扫描分为局限性与晚期状态。
- 按研究人群和肿瘤类型汇总数据,分析观察事件的每两周频率。
主要发现
- 2020年较2019年晚期疾病患者率比为1.56(P<0.001)。
- 2020年较2019年N+或M+患者率比分别为1.84和2.09(P<0.001)。
- 2020年较2019年受累N站数更多或M数量更多的患者率比分别为2.01和2.06(P<0.001)。
- 按肿瘤类型分析,2020年较2019年淋巴瘤和肺癌的晚期疾病显著增加(P<0.001)。
- 2020年较2019年肺癌、胃肠癌、乳腺癌及淋巴瘤患者的淋巴结受累显著增加(P<0.02);肺癌远处转移显著增加(P=0.002)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate whether the COVID-19 pandemic and national lockdown had an impact on the extent of cancer disease at FDG PET/CT staging as surrogate marker. METHODS: Retrospective observational study including cancer patients submitted to FDG PET/CT staging from June 1 to October 31, 2020, and June 1 to October 31, 2019, respectively. Data regarding primary tumour, nodal (N) status and number of involved nodal stations, and presence and number of distant metastases (M) were collected. Each scan was classified in limited vs advanced status. Data were aggregated across the study population and tumour type. Bi-weekly frequencies of the observed events were analysed. RESULTS: Six hundred eleven patients were included (240 in 2019 vs 371 in 2020, respectively). A significant increase of advanced disease patients (rate 1.56, P < 0.001), N + or M + patients (rate 1.84 and 2.09, respectively, P < 0.001), and patients with a greater number of involved N stations or M (rate 2.01 and 2.06, respectively, P < 0.001) were found in 2020 compared with data of 2019. Analysis by tumour type showed a significant increase of advanced disease in lymphoma and lung cancer in 2020 compared with 2019 (P < 0.001). In addition, a significant increase of nodal involvement was found in lung, gastro-intestinal, and breast cancers, as well as in lymphoma patients (P < 0.02). A significant increase of distant metastases was found in lung cancers (P = 0.002). CONCLUSION: Cancer patients with advanced disease at FDG PET/CT staging increased in 2020 compared with 2019, following the national lockdown due to the COVID-19 pandemic, 1.5-fold with a significant increase of patients with N or M involvement. Targeted health interventions are needed to mitigate the effects of the pandemic on patient outcome.
引用
- Caldarella C, Cocciolillo F, Taralli S, et al. The impact of the COVID-19 pandemic on oncological disease extent at FDG PET/CT staging: the ONCOVIPET study. Eur J Nucl Med Mol Imaging. 2021. PMID: 34877609. doi:10.1007/s00259-021-05629-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。